As reported in the July 4, 2012 issue of Nature, an international team of scientists from the Princess Margaret Cancer Centre (Toronto), Weill Cornell Medical College (New York), and Agios Pharmaceuticals (Cambridge, Massachusetts), have discovered a definitive link between a metabolic enzyme and acute myeloid leukemia. Lead by Dr. Tak Mak, Director of the Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital in Toronto, these findings are substantial, as, "for the first time, the cancer scientists have demonstrated how a metabolite can cause cancer." In fact, it is believed that this particular mutation is present in 40% of lymphomas, and is involved in 70%-90% of low-grade brain cancer.
More information about this study is available by clicking here
Study mentioned: Sasaki M et al. IDH1 (R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012 Jul 4 [Epub ahead of print]. PMID 22763442
.
No comments:
Post a Comment